Table 1.
Principal cytogenetic and genetic characteristics associated with high risk of resistance to standard AML therapy*
WBC indicates white blood cell.
*Standard therapy denotes 3+7 induction followed by cytarabine—at doses up to 3 g/m2 for consolidation.
†In contrast to patients with an MK, patients with abnormal karyotype without an MK had a CR rate of 78%.
‡IPK denotes a normal karyotype, or an abnormal karyotype that is not an MK and does not include inv(16) or t(8;21).
§Excluding 15% of patients with CEBPA mutations.
